We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc

Delisted

ALPN was delisted on the 17th of May, 2024.

23 hedge funds and large institutions have $27.4M invested in Alpine Immune Sciences Inc in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 2223 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

43% less capital invested

Capital invested by funds: $48M → $27.4M (-$20.5M)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
23
Holders Change
+1
Holders Change %
+4.55%
% of All Funds
0.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
3
Reduced
7
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$12.1M
FM
2
Frazier Management
Washington
$8.09M
BI
3
BVF Inc
California
$2.37M
DM
4
Deerfield Management
New York
$1.75M -$678K -137,417 -22%
TM
5
Tiger Management
New York
$599K
Victory Capital Management
6
Victory Capital Management
Texas
$501K +$350K +70,980 +109%
HP
7
Hikari Power
Japan
$453K +$607K +122,972 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$441K -$533K -108,052 -47%
Renaissance Technologies
9
Renaissance Technologies
New York
$321K -$133K -26,982 -24%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$140K
Geode Capital Management
11
Geode Capital Management
Massachusetts
$137K
BCM
12
Bridgeway Capital Management
Texas
$132K -$14.8K -3,000 -8%
DS
13
DRW Securities
Illinois
$106K
BlackRock
14
BlackRock
New York
$94K -$1.2K -244 -0.9%
AWCI
15
Alpine Woods Capital Investors
New York
$55K
Morgan Stanley
16
Morgan Stanley
New York
$29K +$32.8K +6,647 +641%
PAM
17
Panagora Asset Management
Massachusetts
$25K -$626 -127 -2%
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$13K
TRCT
19
Tower Research Capital (TRC)
New York
$11K +$8.58K +1,740 +139%
UBS Group
20
UBS Group
Switzerland
$6K +$8.27K +1,676 New
Bank of America
21
Bank of America
North Carolina
$4K +$5.45K +1,105 New
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$3K
Deutsche Bank
23
Deutsche Bank
Germany
$1K -$167K -33,858 -99%
Millennium Management
24
Millennium Management
New York
-$68K -10,694 Closed
State Street
25
State Street
Massachusetts
-$64K -10,126 Closed

ALPN Hedge Fund Activity: Q4 2018 in Review

23 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q4 2018, worth a combined $27.4M — down 43% from $48M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ALPN positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.

The largest buyer was Hikari Power, opening a new position worth an estimated $607K. The largest seller was Deerfield Management, cutting an estimated $678K.

  • 23 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q4 2018, up from 22 in Q3 2018.
  • Funds reported $27.4M of Alpine Immune Sciences Inc stock for Q4 2018, down 43% quarter-over-quarter.
  • 3 funds opened new Alpine Immune Sciences Inc positions in Q4 2018 and 2 closed out, a net change of +1 holder.
  • The largest Alpine Immune Sciences Inc buyer in Q4 2018 was Hikari Power, an estimated $607K added.
  • The largest Alpine Immune Sciences Inc seller in Q4 2018 was Deerfield Management, an estimated $678K sold.

Based on aggregated 13F filings for Q4 2018.